Mid-Atlantic Division
Cancer Diagnosis Program (CDP) Breast Cancer Stage I, II, & III Prognostic TMA Data
Annotation Data Overview
Data that are provided for each case include age at diagnosis, year of diagnosis, tumor size, laterality, TNM stage, number of nodes positive, number of nodes examined, type of surgery, type of therapy, histologic type, tumor grade, overall survival, and recurrence free survival.
| Data Variable | Description | Coding |
|---|---|---|
| Age | Age at initial diagnosis | Integer or blank |
| Year | Year of initial diagnosis | Integer or blank |
| Primary Histology | Most prominent Histologic type | 01 = Ductal (NOS) 08 = Lobular |
| Secondary Histology | Secondary Histology Secondary Histologic type (if any) | 00 = None 01 = Ductal (NOS) 02 = Tubular 03 = Papillary 04 = Mucinous 05 = Medullary 06 = Cribiform 07 = Adenoid Cystic 08 = Lobular 09 = Mixed Lobular/Ductal 88 = Other, specify |
| Laterality of primary breast cancer | Origin of the primary breast cancer | 1 = Right 2 = Left 9 = Unknown |
| T Stage | AJCC (version 5) T stage | Stage I/II/III Prognostic TMAs: T1 = Tumor < 20 mm T1a = Tumor < 5 mm T1b = Tumor > 5 mm and < 10 mm T1c = Tumor > 10 mm and < 20 mm Stage II/III Prognostic TMAs only: T2 = Tumor > 20 mm and < 50 mm T3 = Tumor > 50 mm Stage III Prognostic TMA only: T4 = Tumor any size + extension T4a = Extension to chest wall T4b = Edema or ulceration or satellite skin nodules T4c = Both T4a and T4b T4d = Inflammatory carcinoma |
| N Stage | AJCC (version 5) N stage | Stage I/II/III Prognostic TMAs: N0 = No evidence of regional LN involvement Stage II/III Prognostic TMAs only: N1 = Mets to movable, ipsilateral node N1a = Only micromets (< 2 mm) N1b = Any nodal mets > 2 mm N1b1 = Mets to 1-3 nodes, any > 2 mm and all <20 mm="" br=""> N1b2 = Mets to 4 or more nodes, any > 2 mm and all < 20 mm N1b3 = Extension of tumor beyond node capsule, < 20 mm N1b4 = Mets to nodes > 20 mm Stage III Prognostic TMA only: N2 = Mets to ipsilateral nodes that are fixed to one another or to other structures N3 = Mets to ipsilateral internal mammary lymph node NX = Minimum requirement not met (unknown) |
| M Stage | AJCC (version 5) M stage | M0 = No known distant metastases |
| Tumor Size | Measurement (in cm) of the longest diameter of the tumor | Integer or blank |
| Number of Nodes Positive | Number of nodes positive at initial diagnosis | 00 = All nodes negative 01-96 = Number of nodes positive 97 = 97 or more nodes positive 98 = Positive nodes, number unspecified 99 = Unknown if nodes positive or negative |
| Number of Nodes Examined | Number of nodes examined at initial diagnosis | 00 = No nodes examined 01-96 = Number of nodes examined 97 = 97 or more nodes examined 98 = Nodes examined, number unspecified 99 = Unknown if nodes examined |
| Type of Surgery | Type of the most comprehensive procedure performed as part of the initially planned surgery | 00 = Biopsy, NOS 10 = Partial Mastectomy WITHOUT Axillary Lymph Node Dissection 20 = Partial Mastectomy WITH Axillary Lymph Node Dissection 30 = SubQ Mastectomy WITH OR WITHOUT Axillary Lymph Node Dissection 40 = Mastectomy WITHOUT Axillary LymphNode Dissection 50 = Mastectomy WITH Axillary LymphNode Dissection 60 = Radical Mastectomy WITH Dissection of Majority of Pectoralis Major WITH Axillary LymphNode Dissection 90 = Mastectomy, NOS |
| Tubule Formation | Percentage of tubular structures | 1 = > 75 % 2 = > 10 to > 75 % 3 = < 10% |
| Nuclear Pleomorphism | Qualitative and quantitative evaluations of the nuclei | 1 = When the tumor cell nuclei are small with regular outlines, vary little in size and have uniform nuclear chromatin 2 = When the tumor cell nuclei are larger than normal, have open vesicular nuclei with visible nucleoli and have a moderate variability in size and shape 3 = When nuclei show marked variation is size and shape, especially when there are bizarre shapes, and/or prominent enlarged or multiple nucleoli |
| Mitotic Counts | Mitotic counts are to be performed at the periphery of the tumor. Ten high power fields are counted. | Field area in mm2: ‚ÄÉ‚ÄÉ0.152‚ÄÉ‚ÄÉ0.175‚ÄÉ‚ÄÉ0.200‚ÄÉ‚ÄÉ0.225‚ÄÉ‚ÄÉ0.250‚ÄÉ‚ÄÉ0.275 1=‚ÄÉ0-5‚ÄÉ‚ÄÉ‚ÄÉ0-7‚ÄÉ‚ÄÉ‚ÄÉ0-7‚ÄÉ‚ÄÉ‚ÄÉ0-7‚ÄÉ‚ÄÉ‚ÄÉ0-8‚ÄÉ‚ÄÉ‚ÄÉ0-9 2=‚ÄÉ6-10‚ÄÉ‚ÄÉ7-12‚ÄÉ‚ÄÉ‚ÄÉ8-13‚ÄÉ‚ÄÉ‚ÄÉ8-15‚ÄÉ‚ÄÉ9-17‚ÄÉ‚ÄÉ10-18 3=‚ÄÉ>10‚ÄÉ‚ÄÉ‚ÄÉ>12‚ÄÉ‚ÄÉ‚ÄÉ>13‚ÄÉ‚ÄÉ‚ÄÉ>15‚ÄÉ‚ÄÉ‚ÄÉ>17‚ÄÉ‚ÄÉ‚ÄÉ>18 |
| Tumor Grade | Total score calculated from the extent of tubule formation, nuclear pleomorphism, and mitotic count. | 1 = Grade I 2 = Grade II 3 = Grade III |
| Chemotherapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
| Radiation therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
| Hormone therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
| Immunotherapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
| Other Therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
| Vital Status | Vital status at last contact | 1 = Alive 2 = Dead |
| Length of follow-up for overall survival (OS) | Number of months from date of diagnosis to date of death due to any cause, or to date last known alive. | Integer or blank |
| Cancer status at death (if deceased) | Any evidence of the breast cancer at the time of death. | 0 = No evidence of breast cancer 1 = Evidence of this primary breast cancer (includes never disease-free, recurrent or metastatic cancer from primary). 2 = Another cancer is present, or the cancer present is of undetermined origin. 9 = Unknown |
| Type/site of first recurrence (if any) outside of ipsilateral breast | The first recurrence outside of the ipsilateral breast. Applicable only if patient was disease free after initial surgery. | 0 = None 1 = Chest wall (local) 2 = Ipsilateral axillary nodes or within the axilla if no nodes are mentioned (regional) 3 = Distant (includes distant nodes) 4 = Never disease-free 5 = Non-ipsilateral breast recurrence, but type/site not specified 6 = Recurred, but unknown if in ipsilateral breast or not in ipsilateral |
| Site of distant recurrence | Site of distant recurrence, if any. Applicable only if patient was disease free after initial surgery. | 01 = Skin 02 = Lymph Nodes 03 = Bone 04 = Lung 05 = Pleura 06 = Liver 07 = CNS 08 = Peritoneum 88 = Other 99 = Unknown NA = Not applicable |
| Length of follow-up for first recurrence outside of ipsilateral breast | Number of months from date of diagnosis to date of first recurrence outside of the ipsilateral breast. | Integer or blank |
| Indicator of ipsilateral breast recurrence | Ipsilateral breast recurrence. Applicable only if surgery was breast-conserving and patient was disease free following initial surgery. | 0 = No 1 = Yes NA = not applicable |
| Length of follow-up for ipsilateral breast recurrence | Number of months from date of diagnosis to date of first ipsilateral in-breast recurrence, or to date last verified free of ipsilateral recurrence. | Integer or NA |
| Type of first recurrence-free survival (RFS) event observed | First observed RFS event (ipsilateral invasive breast tumor recurrence, local/regional recurrence, distant recurrence, death due to any cause, or none). Applicable only if patient was disease free after initial surgery. | 1 = Death due to any cause 2 = Distant recurrence 3 = Ipsilateral recurrence 4 = Local/regional recurrence 5 = None 6 = Unknown |
| Length of follow-up for recurrence-free survival (RFS) | Number of months from date of diagnosis to the date of first ipsilateral invasive breast tumor recurrence, local/regional recurrence, distant recurrence, or death due to any cause. Applicable only if patient was disease free after initial surgery. | Integer or blank |
| ER Score | ASCO CAP Guidelines for ER Scoring | 0 = Negative (< 1% expressing cells) 1 = Positive (= 1% expressing cells) NA = Not applicable |
| PR Score | ASCO CAP Guidelines for PR Scoring | 0 = Negative (< 1% expressing cells) 1 = Positive (= 1% expressing cells NA = Not applicable |
| HER2 IHC | ASCO CAP Guidelines for HER2 Scoring | 0 = No staining 1 = Weak, incomplete membrane staining in any proportion of invasive tumor cells, or weak, complete membrane staining in less than 10% of cells. 2 = Complete membrane staining that is non-uniform or weak but with obvious circumferential distribution in at least 10% of cells, or intense complete membrane staining in 30% or less of tumor cells. 3 = Uniform intense membrane staining of more than 30% of invasive tumor cells. NA = Not applicable |
| HER2 FISH | ASCO CAP Guidelines for HER2 Scoring | 0 = Not amplified 1 = Amplified |
| HER2 Score | Final HER2 result that is a combination of the HER2 IHC and FISH evaluations. HER2 FISH was performed for all 1+ and 2+ HER2 IHC results. | 0 = Negative: IHC Score 0; or IHC Score 1+ or 2+ and HER2 not amplified with FISH 1 = Positive: IHC score 3+; or IHC Score 1+ or 2+ and HER2 amplified with FISH |
| Comments | Information known about prior or subsequent primary cancers (breast or non-breast) and their recurrences (if any), and any other information pertinent to the interpretation of the case's data. | Text or blank |
 
Array Maps, Annotation Keys and Datafiles
Below are downloadable files containing the complete annotation data for these TMAs. No additional data is available. Please contact the Mid-Atlantic Division with any questions.
- CDP Breast Cancer Stage I Prognostic
- CDP Breast Cancer Stage II Prognostic
- CDP Breast Cancer Stage III Prognostic
Back    Return to top